Active substance
Results for the substance fluticasone furoate umeclidinium vilanterol
2 results
About this active substance
The combination of fluticasone furoate, umeclidinium, and vilanterol is used to treat chronic obstructive pulmonary disease (COPD) and, in some cases, severe asthma. Fluticasone furoate reduces airway inflammation, umeclidinium relaxes bronchial muscles through anticholinergic action, and vilanterol is a long-acting bronchodilator. Together, these substances help improve breathing and prevent disease worsening.
The medication is administered by inhalation, usually once a day at the same time, as directed by your doctor. Regular use is essential to maintain symptom control and prevent COPD exacerbations or asthma attacks.
Side effects may include throat irritation, oral infections, dry mouth, headache, or palpitations. Rarely, severe allergic reactions or worsening of respiratory symptoms may occur. If you experience difficulty breathing or facial swelling, contact your doctor immediately.
The combination of fluticasone furoate, umeclidinium, and vilanterol is effective in managing COPD and severe asthma, but correct use and medical monitoring are necessary to ensure the safety and effectiveness of the treatment.
The medication is administered by inhalation, usually once a day at the same time, as directed by your doctor. Regular use is essential to maintain symptom control and prevent COPD exacerbations or asthma attacks.
Side effects may include throat irritation, oral infections, dry mouth, headache, or palpitations. Rarely, severe allergic reactions or worsening of respiratory symptoms may occur. If you experience difficulty breathing or facial swelling, contact your doctor immediately.
The combination of fluticasone furoate, umeclidinium, and vilanterol is effective in managing COPD and severe asthma, but correct use and medical monitoring are necessary to ensure the safety and effectiveness of the treatment.